A Cell-State Systems Biology Framework for Precision Oncology

New paradigm integrates single-cell transcriptomics, regulatory network inference, and AI to decode—and therapeutically target—the multiple, co-existing cancer cell states that drive resistance in pancreatic cancer, glioblastoma, and other lethal malignancies

NEW YORK, Aug. 26, 2026 /PRNewswire/ -- DarwinHealth, a New York-based, AI-centric biotechnology company. today announced the introduction of Quantum Cancer Biology: A Cell-State Systems Biology Framework for Precision Oncology, a transformative scientific paradigm designed to address one of oncology's greatest unsolved challenges: why the world's deadliest cancers continue to evade even the most advanced targeted therapies.

The announcement accompanies the publication in Nature Genetics (https://www.nature.com/articles/s41588-026-02714-8) of a new perspective led by Dr. Andrea Califano and Dr. Kenneth P. Olive, driven by first author Dr. Pasquale Laise, PhD, alongside co-first authors Mikko Turunen, PhD, and Alvaro Curiel-Garcia, PhD.

The study, conducted at Columbia University, presents original research findings and argues that the next revolution in oncology will not come from discovering a single "miracle drug," but from longitudinally decoding the multiple malignant cellular states that coexist within advanced, treatment-resistant tumors in individual patients.

The framework, undergirded by the company's proprietary VIPER technology, licensed by Columbia exclusively to DarwinHealth, is supported by pioneering research led by DarwinHealth scientists Pasquale Laise, Mariano J. Alvarez, Andrea Califano, and their collaborators. Their single-cell systems biology studies, including the just published Nature Genetics report, demonstrate that pancreatic cancers comprise not one, but multiple, biologically distinct malignant cell states, each governed by unique regulatory programs and therapeutic vulnerabilities. 

From a landscape-changing perspective, this is the first study to convincingly show that vulnerabilities and desired drug responses among multiple cancer cell states that coexist in an individual patient's tumor (in this case, pancreatic cancer) are virtually identically conserved in patients with the same kind of cancer. In other words, at the time of disease onset, all patients with a particular kind of cancer—pancreatic cancer, glioblastoma, breast cancer, melanoma, prostate cancer, and many others—harbor a recurring, predictable, and co-existing mix of multiple cancer cell state abnormalities, all of which must be targeted relatively simultaneously to achieve optimal treatment results.

Schreibe Deinen Kommentar